financial guidance

The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.

The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.

The company sold nearly twice as many tests as in Q2 last year, with clinical test revenue more than doubling and total revenue reaching $54 million for the quarter.

The firm reported revenues of $13.6 million and raised full-year revenue guidance, but revised full-year earnings guidance downward.

Mass cytometry revenues increased 28 percent to $17.5 million year over year, but microfluidics revenues dropped 16 percent to $10.7 million.

The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.

The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.

The firm's molecular diagnostics revenue increased nearly 11 percent with global sales of $170.9 million.

The firm's flow cytometry business contributed about $13.2 million, or 16 percent of the firm's consolidated revenue in the second quarter.

Much of the growth was driven by contributions from Genoptix, which NeoGenomics acquired in late 2018. Organically, revenues were up 20 percent.